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ABSTRACT 
Aim: Circadian variation in human ventricular fibrillation (VF) dominant frequency is 
unknown.  If present this would provide evidence of physiological influence on VF. The 
objective was to quantify the circadian variation in human VF dominant frequency. 
Methods: Eight-lead Holter ECG recordings were obtained from a patient with VF who was 
supported by a bi-ventricular assist device.  Recordings of up to 24 h duration were 
obtained on 6 days with an average interval between recordings of 7 days.  Dominant 
frequency and amplitude were obtained using spectral analysis and assessed for i) 
circadian, ii) inter-recording and iii) inter-lead differences. 
Results: There was a significant circadian variation in amplitude (night: 0.027±0.004 mV 
Hz vs day: 0.044±0.006 mV Hz, p < 0.0001) but not dominant frequency (night: 7.85±0.62 
Hz vs day: 7.93±0.54 Hz, p > 0.05).  There were significant differences between 
recordings in dominant frequency which ranged from 6.80±0.29 Hz to 8.36±0.38 Hz (p < 
0.0001) and dominant frequency spectral amplitude which ranged from 0.033±0.014 mV 
Hz to 0.043±0.017 mV Hz (p < 0.0001).  Histograms of dominant frequencies in leads 
exhibited strikingly different distributions, particularly in V2 that was characterised by a 
bimodal distribution, while the other leads were characterised by predominantly unimodal 
distributions. 
Conclusion: VF dominant frequency spectral amplitude exhibits circadian variability.  
These results provide evidence for modulation of VF, probably induced by changes in 
posture and physical activity. 
Keywords: Ventricular fibrillation, dominant frequency, circadian variability 
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1. Introduction 
The cardiovascular system exhibits circadian variability that is thought to promote a 
healthy balance between the sleep/wake cycle (1).  For example, impaired circadian 
patterns in blood pressure and heart rate have prognostic significance (2,3).  The 
autonomic nervous system plays a key role in mediating this cycle (4).  On one hand, 
circadian variability is an essential characteristic of a healthy cardiovascular system, yet it 
also seems to provide a window of opportunity for adverse cardiovascular events at certain 
times of the cycle.  Particularly, incidence of sudden cardiac death increases in the 
morning (5), as does onset of ventricular arrhythmias (6-9).  These increases probably 
relate to the circadian pattern of myocardial infarction (10).  It has been suggested that 
circadian changes in cardiac electrophysiological properties, for example, ventricular 
refractoriness that shortens during the morning, also contributes to the circadian cycle of 
arrhythmogenicity (11).  Additionally, Vendetti et al (12) demonstrated in patients with 
implantable cardioverter-defibrillators significantly increased defibrillation threshold during 
the morning and increased numbers of failed defibrillation attempts in the morning 
compared to other periods of the day.  The study did not present data for defibrillation 
thresholds or failures at night.  Defibrillation success has been associated with lower VF 
dominant frequency and larger ECG waveform amplitude (13-15).  Hence, diurnal 
variations in these parameters might help to explain the observed diurnal patterns of 
defibrillation success. 
The aim of our study was to assess circadian variability in human VF dominant frequency 
and amplitude.  Dominant frequency is an important parameter related to the frequency of 
underlying re-entrant circuits or triggers that sustain the arrhythmia (16, 17).  The dominant 
frequency spectral amplitude is a measure of the power contained in the ECG at the 
dominant frequency.  We have already reported the spatial and temporal variability in 
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dominant frequency in short duration ECG recordings of human VF (18).  However, due to 
the difficulty of obtaining recordings of sufficient duration, the circadian variation of 
dominant frequency is unknown. 
2. Methods 
2. 1. Patient characteristics  
The patient was a 29 year old female admitted to the Freeman Hospital with cardiogenic 
shock due to viral myocarditis.  A Berlin Heart Biventricular Assist Device was implanted, 
and the patient underwent heart transplantation three months later, though subsequently 
died in the early post-operative period. Histological examination of the explanted heart 
revealed appearances of a fibro-inflammatory cardiomyopathy in keeping with post-acute 
lymphocytic myocarditis though with no morphological features as to the aetiology. There 
was serological evidence of a recent adenoviral infection at the time of presentation. 
Shortly after implantation of the ventricular assist device the patient developed sustained 
VF.  The patient was not prescribed any cardiac medication or anti-arrhythmics. There 
were no significant serum electrolyte abnormalities. Despite the VF the patient recovered 
well on biventricular support, enough to allow home visits. The settings of the device (rate, 
systolic and diastolic pressures) were kept constant throughout the assist device support 
period. The cause of death after transplantation was primary graft failure.  Informed 
consent and ethical approval were obtained to conduct this study. 
2.2. Data recording and dominant frequency analysis 
Eight-lead Holter ECG (H12+, Mortara, Italy) recordings were obtained from the patient on 
six separate days.  The first recording (day 1) was obtained 26 days after implantation of 
the assist device.  The mean interval between recordings was 7 days (range 5 to 10).  Five 
recordings were 24 hours duration and one was limited to 18 hours due to patient request.  
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No recordings were available at VF onset and VF did not terminate.  ECGs were recorded 
at a sample rate of 1000 Hz and stored on computer for subsequent processing and 
analysis.  ECGs were filtered using a 6th order Butterworth filter with pass band of 0.5 to 30 
Hz to minimise baseline and movement artefact while preserving the fibrillation signal. 
Spectral analysis using the Fast Fourier Transform was applied to contiguous 1-minute 
segments of the ECG recordings, and dominant frequency and amplitude were determined 
for each segment.  Spectra were visually inspected to see if they exhibited harmonic peaks 
sometimes observed in highly organised ventricular arrhythmias that might have hindered 
the detection of the dominant spectral peak but there was none.  Herein dominant 
frequency refers to the frequency with the largest spectral amplitude measured in Hz and 
amplitude refers to the amplitude of the spectrum at the dominant frequency measured in 
mV Hz.  Amplitude is an indirect measure of the power of signal components at different 
frequencies.  Frequency resolution of the spectra was 0.015 Hz.  Signal processing and 
analysis was carried out using Matlab R2009b (The Mathworks Inc, USA).  Differences in 
dominant frequency and amplitude were quantified i) between day and night, ii) between 
recordings, and iii) between ECG leads. 
2.3. Statistical analysis 
Circadian variation in dominant frequency and amplitude were assessed by comparing 
differences in mean day (08:00 to 00:00, comprising morning: 08:00 to 12:00, and 
afternoon/evening: 12:00 to 00:00) and night (00:00 to 08:00) values using the Wilcoxon 
rank sum test. Differences between recordings and leads were assessed by Kruskal-Wallis 
test.  A p value less than 0.05 was used to indicate statistical significance. Summary 
values are shown as mean±sd unless otherwise stated.  Statistical analysis was carried 
out using Matlab Statistical Toolbox R2009b. 
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3. Results 
3.1 Spectral parameters 
Figure 1, left panel, shows the minute-by-minute dominant frequency and amplitude for 
each recording.  The right panel shows histograms of dominant frequency for each 
recording. The most notable observations were that i) there was clear circadian variation in 
amplitude, and ii) dominant frequency changed between recordings. 
3.2. Circadian differences in spectral parameters 
Figure 2 summarises the mean day and night dominant frequency and amplitude for each 
recording.  Amplitude was significantly reduced at night compared to day (0.027±0.004 vs 
0.044±0.006 mV Hz, p < 0.0001).  This indicated that the amplitude during the day is on 
average 1.63 (0.044/0.027) times that at night.  In a sub-analysis of morning and 
afternoon/evening values, there was a significant reduction in amplitude from morning to 
afternoon/evening (0.055±0.011 vs 0.041±0.006 mV Hz, p < 0.01) and a further significant 
reduction from afternoon/evening to night (0.041±0.006 vs 0.027±0.004 mV Hz, p < 0.003).  
However, dominant frequency did not change significantly from night to day (7.85±0.62 vs 
7.93±0.54 Hz, p > 0.05).  To illustrate the circadian variation of the ECG figure 3 illustrates 
representative sections of day and night ECGs of 10 s duration alongside their associated 
spectra.  Both ECG and spectral amplitude are clearly increased in the day compared to 
night. 
3.3. Differences between recordings 
Figure 4 summarises dominant frequency and amplitude from recordings on different days.  
There were significant differences in both dominant frequency (p < 0.0001) and amplitude 
(p < 0.0001).  Dominant frequency ranged from 6.80±0.29 Hz on day 1 to 8.36±0.38 Hz on 
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day 22. Amplitude ranged from 0.033±0.014 mV Hz on day 22 to 0.043±0.017 mV Hz on 
day 36. 
3.4. Differences between leads 
Figure 5 shows histograms of dominant frequency from each lead.  The histogram 
distributions were not equal for all leads.  Particularly V2 for all recordings exhibited a 
bimodal distribution whereas the other leads predominantly exhibited a unimodal 
distribution.  Table 1 describes the similarity of distributions between leads by quantifying 
the percentage overlap (area under the curves) in the distributions.  Values are average 
for the six recordings.  V2 distributions exhibited the least similarity with the other lead 
histograms with approximately 50% overlap.  Figure 6 compares by lead the dominant 
frequencies with the greatest histogram count for each recording.  For V2 the dominant 
frequencies with the greatest histogram count for each peak in the bimodal histogram 
distribution were identified as indicated by the two boxplots in figure 6.  There were 
significant differences between leads for the lowest V2 dominant frequency (p < 0.02) but 
no significant difference for the highest V2 dominant frequency (p > 0.05). 
4. Discussion 
This is the first study to quantify circadian variations in human VF dominant frequency and 
amplitude.  VF is typically sustained for seconds rather than hours so there has been a 
paucity of data of sufficient duration to allow assessment of circadian variations of VF 
dominant frequency. Patients developing VF who are supported by ventricular assist 
devices provide a novel model that facilitates the study of human VF over much longer 
periods, typically weeks or months, than any other model.  Using this model we have 
collected a unique dataset and quantified the circadian pattern of VF spectral 
characteristics repeatedly in the same patient over several weeks. The obvious difference 
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of this model to normal VF is that the assist device ensures the heart remains continuously 
perfused.  This is not a restriction in our study because we were interested in the circadian 
pattern of VF rather than the effects of ischaemia.  We have demonstrated a circadian 
pattern that was characterised by significant reductions in VF amplitude at night.  Postural 
changes are the most plausible explanation for this circadian pattern, particularly since 
day-time amplitudes exhibited large variability reflecting the relatively active state of this 
patient whereas night-time amplitudes, when the patient would be expected to be 
sedentary, were relatively constant.  However, autonomic influences may also contribute 
to the circadian pattern of VF. As discussed in the introduction, the effect of the autonomic 
nervous system on a range of cardiac parameters is well established.  Circadian changes 
in atrial fibrillation dominant frequency have been reported with significantly reduced cycle 
length (increased dominant frequency) during daytime, but not in patients with already 
short cycle lengths (18).  In our study dominant frequency of VF did not change 
significantly from day to night suggesting there is no autonomic influence on VF dominant 
frequency. Defibrillation success has been related to organisation of VF (13, 14).  It is 
interesting that in our patient VF was more organised, as suggested by increased 
waveform amplitude, in the morning, when previous studies have indicated that 
defibrillation success is lowest (12).  Although there was no circadian pattern of VF 
dominant frequency, there were significant inter-recording and inter-lead differences in 
dominant frequency.  This is the second case of long-term VF data from our group and the 
results confirm our previously published data which revealed significant inter-recording and 
inter-lead differences in dominant frequency (19). Inter-lead differences in dominant 
frequency probably reflect spatial differences in underlying activation patterns that have 
been shown in invasive human studies (20).  Day-to-day variability in dominant frequency 
might arise due to changes in the cardiac electrophysiological properties due to 
progression of disease.  
 9
5. Conclusion 
In this novel model of human VF sustained over several weeks we have shown a circadian 
pattern of VF amplitude but not dominant frequency.  These results provide evidence for 
modulation of VF, probably induced by changes in posture and physical activity. 
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Figure legends 
Figure 1  Left panel: Dominant frequency (DF) and amplitude (Amp) across each 
recording.  Median dominant frequency is shown in red and the range across leads in blue.  
Amplitude (mV Hz) was scaled by times 50 and is shown in black.  Right panel: 
Histograms of dominant frequency for each of the recordings. 
Figure 2 Comparisons of night and day dominant frequency (DF) and amplitude (Amp.).  
There were no significant differences for dominant frequency (p > 0.05) but amplitude was 
significantly increased during the day (p < 0.0001). 
Figure 3.  Examples of ECG leads and corresponding spectra from night and day.  For 
both night and day each row shows an ECG lead of 10 s duration and the power spectrum 
calculated from a 1 minute interval of ECG containing the illustrated ECG section. 
Figure 4.  Boxplots of dominant frequency (DF) and amplitude (Amp.) at each recording.  
There were significant differences between recordings of both dominant frequency and 
amplitude.  Box represents the interquartile range (IQR: q3-q1) of data and median is 
shown as a line.  Whiskers represent points within q1 – 1.5 x IQR and q3 + 1.5 x IQR. 
Figure 5.  Histograms of dominant frequency for each lead and recording. 
Figure 6. Boxplot of dominant frequency for each lead. The dominant frequency with the 
maximum count for each recording was used to construct the boxplot for each lead.  Two 
boxplots for V2 represent the bimodal distribution of the histogram. 
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Table 1.  Similarity of lead dominant frequency distributions shown in figure 5.   
Lead I II V1 V2 V3 V4 V5 V6 
I 100 83 59 53 79 80 83 80 
II - 100 65 56 74 77 83 81 
V1 - - 100 59 58 57 58 55 
V2 - - - 100 53 48 48 45 
V3 - - - - 100 85 76 72 
V4 - - - - - 100 82 77 
V5 - - - - - - 100 88 
V6 - - - - - - - 100 
Values are the average percentage overlap of area under the curves of lead dominant 
frequency histograms over the six recordings.  The distributions for lead V2 (bold) had 
least similarity to the distributions of the other leads. 
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